Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin

NEKTAR THERAPEUTICS

Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).
In uncontrolled asthma subset (ACQ-5≥1.5, n=25), all doses showed significant ACQ-5 improvement; placebo-adjusted reductions 1.0–1.4.
Placebo crossover (n=42) at week 24: EASI-75 60%, vIGA-AD 0/1 33%, EASI-90 37%, Itch NRS response 50%.
Data support 24 μg/kg q2w dose with 24-week induction period for Phase 3 studies.
Top-line Phase 2b data in alopecia areata expected December 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.